The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•29 March 2026•

1 min read

BlackRock Health Sciences Trust Upgraded to Buy Following Strategic Shift

Key Facts

1BlackRock Health Sciences Trust (BME) was upgraded to a 'buy' rating following a strategic shift toward an equity-focused strategy.

2The trust eliminated its option writing strategy to better capture upside and improve Net Asset Value (NAV) growth.

3The fund offers an 8.3% monthly dividend yield, though coverage relies on realized capital gains rather than stable income.

Create Free Account

BlackRock Health Sciences Trust (BME) has been upgraded to a 'Buy' rating following a significant pivot in its investment strategy toward an equity-focused approach. The trust has eliminated its previous option writing strategy to better capture upside potential and improve Net Asset Value (NAV) growth. This strategic shift is designed to allow the fund to participate more fully in healthcare sector gains, particularly within the high-growth GLP-1 drug segment. While the fund maintains an attractive monthly dividend yield of 8.3%, coverage now relies more heavily on realized capital gains. Analysts suggest that removing the income-generating caps allows the fund to capitalize on broader market rallies. This move positions BME as a more aggressive growth vehicle for investors targeting medical innovation.